WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • WJPPS: MARCH ISSUE PUBLISHED
  • March Issue has been successfully launched on 1 March 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

Abstract

SODIUM GLUCOSE CO-TRANSPORTER-2 INHIBITORS - OVERVIEW

Anteneh Tamirat*, Jagdish Kakadiya and Shiv Kumar Rathod

ABSTRACT

Type 2 Diabetes mellitus (T2DM) is characterized by an increase in blood glucose level due to the resistance of pancreatic hormone; insulin secretion and action. Cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) have attained epidemic proportions worldwide, becoming increasingly alarming public health problems. A growing body of evidence suggests that there is a strong links or relationship between T2DM, CVD and hypertension. Sodium–glucose co transporter-2 (SGLT-2) is a new molecular target to directly induce glucose excretion and to safely normalize plasma glucose in type 2 diabetes. The SGLT-2 protein is a high capacity molecule responsible for the majority of glucose reuptake with pharmacological inhibition, resulting in the loss of about 80g of glucose in the urine each day. Sodium–glucose co transporter-2 (SGLT-2) inhibitors have a unique mechanism of action, which is independent of insulin secretion and insulin action. This unique mechanism of action, in addition to lowering plasma glucose, corrects a number of metabolic and hemodynamic abnormalities that are risk factors for CVD.

Keywords: Type-2 diabetes mellitus, SGLT-2 inhibitor, Cardiac complication.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More